Moïse Namer

7.6k total citations
62 papers, 2.8k citations indexed

About

Moïse Namer is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Moïse Namer has authored 62 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 25 papers in Cancer Research and 16 papers in Genetics. Recurrent topics in Moïse Namer's work include Cancer Treatment and Pharmacology (27 papers), Breast Cancer Treatment Studies (23 papers) and Estrogen and related hormone effects (11 papers). Moïse Namer is often cited by papers focused on Cancer Treatment and Pharmacology (27 papers), Breast Cancer Treatment Studies (23 papers) and Estrogen and related hormone effects (11 papers). Moïse Namer collaborates with scholars based in France, United States and Italy. Moïse Namer's co-authors include M. Spielmann, G. Milano, P. Fumoleau, Miguel Martín, C.M. Lalanne, Pierre Kerbrat, M. Schneider, A. Thyss, Clifford A. Hudis and Kathy S. Albain and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Moïse Namer

62 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Moïse Namer France 25 1.8k 1.1k 496 437 419 62 2.8k
Carsten Rose Sweden 28 1.2k 0.7× 998 0.9× 522 1.1× 602 1.4× 514 1.2× 69 2.4k
David L. Ahmann United States 29 1.8k 1.0× 882 0.8× 710 1.4× 637 1.5× 460 1.1× 70 3.1k
D C Tormey United States 32 2.1k 1.2× 1.1k 1.0× 644 1.3× 561 1.3× 718 1.7× 55 3.6k
Reena S. Cecchini United States 20 1.8k 1.0× 959 0.9× 1.1k 2.1× 393 0.9× 422 1.0× 49 2.9k
Darcy Spicer United States 29 2.0k 1.2× 813 0.7× 846 1.7× 880 2.0× 675 1.6× 91 3.8k
Elisabet Lidbrink Sweden 24 1.7k 1.0× 832 0.8× 343 0.7× 315 0.7× 628 1.5× 51 2.4k
Tom Meade United Kingdom 14 1.2k 0.7× 1.0k 0.9× 456 0.9× 679 1.6× 622 1.5× 23 3.9k
Jeremy Braybrooke United Kingdom 23 1.4k 0.8× 979 0.9× 383 0.8× 1.0k 2.3× 674 1.6× 64 2.9k
Takuma Nemoto United States 29 1.6k 0.9× 1.1k 1.0× 696 1.4× 856 2.0× 468 1.1× 57 3.5k
Harriet Johansson Italy 29 1.0k 0.6× 710 0.6× 845 1.7× 846 1.9× 273 0.7× 83 2.5k

Countries citing papers authored by Moïse Namer

Since Specialization
Citations

This map shows the geographic impact of Moïse Namer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moïse Namer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moïse Namer more than expected).

Fields of papers citing papers by Moïse Namer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moïse Namer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moïse Namer. The network helps show where Moïse Namer may publish in the future.

Co-authorship network of co-authors of Moïse Namer

This figure shows the co-authorship network connecting the top 25 collaborators of Moïse Namer. A scholar is included among the top collaborators of Moïse Namer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moïse Namer. Moïse Namer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scotté, Florian, Christian Hervé, Jean‐Marc Tourani, et al.. (2017). Supportive Care Organization in France: a national in-depth survey among patients and oncologists. Supportive Care in Cancer. 25(7). 2111–2118. 9 indexed citations
2.
Joly, Florence, Denis Querleu, Moïse Namer, & Éric Pujade-Lauraine. (2017). Mise à jour 2016 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire et du col de l’utérus à un stade avancé. Bulletin du Cancer. 104. S1–S5. 2 indexed citations
3.
4.
Extra, Jean-Marc, Anne Vincent‐Salomon, T. Delozier, et al.. (2010). Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study. The Oncologist. 15(8). 799–809. 92 indexed citations
5.
Tubiana-Hulin, M., M. Spielmann, Christian Roux, et al.. (2008). Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Critical Reviews in Oncology/Hematology. 71(1). 12–21. 29 indexed citations
6.
Eisinger, François, L. Cals, Jean‐Yves Blay, et al.. (2008). Impact of organised programs on colorectal cancer screening. BMC Cancer. 8(1). 19 indexed citations
7.
Gligorov, Joseph, et al.. (2007). Actualités de la gemcitabine dans le cancer du sein métastatique. Bulletin du Cancer. 94(3). 90–94. 1 indexed citations
8.
Hortobágyi, Gabriel N., Jaime de Salazar, Kathleen I. Pritchard, et al.. (2005). The Global Breast Cancer Burden: Variations in Epidemiology and Survival. Clinical Breast Cancer. 6(5). 391–401. 465 indexed citations
9.
Ferrero, Jean-­Marc, Nicolas Magné, Cyril Foa, Rémy Largillier, & Moïse Namer. (2003). Tolérance cardiaque des associations paclitaxel-anthracyclines dans le cadre de la prise en charge du cancer du sein. Bulletin du Cancer. 90(3). 219–226. 3 indexed citations
10.
François, Éric, et al.. (2002). Palliative 5-Fluorouracil-Based Chemotherapy for Advanced Colorectal Cancer in the Elderly. American Journal of Clinical Oncology. 25(2). 126–130. 32 indexed citations
11.
Eisinger, François, Marc Espié, Christine Lasset, et al.. (1998). La chimioprévention du cancer du sein. Bulletin du Cancer. 85(8). 1 indexed citations
12.
Fontana, Xavier, et al.. (1998). Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S-transferase mu1 gene in primary breast cancers: an update with an additional 114 cases. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 403(1-2). 45–53. 19 indexed citations
13.
Delozier, T., O. Switsers, Michel Héry, et al.. (1997). Late delayed adjuvant tamoxifen in early breast cancer. Results of a cooperative randomized trial. Bulletin du Cancer. 84(1). 25–30. 1 indexed citations
14.
Ferrero, Jean-­Marc, Moïse Namer, Jean‐François Dufour, et al.. (1997). Neoadjuvant chemotherapy of locally advanced breast cancer: historical comparison of 4 sequential combinations. Bulletin du Cancer. 84(1). 1 indexed citations
15.
Delozier, T., O. Switsers, Michel Héry, et al.. (1997). Tamoxifène adjuvant retardé dans le cancer du sein curable. Résultats d’un essai coopératif randomisé. Bulletin du Cancer. 84(1). 25–30. 3 indexed citations
16.
Namer, Moïse. (1993). Anthracyclines in the Adjuvant Treatment of Breast Cancer. Drugs. 45(Supplement 2). 4–9. 4 indexed citations
17.
Etienne, Marie‐Christine, G. Milano, M. Strolin Benedetti, et al.. (1991). Improved Bioavailability of a New Oral Preparation of Medroxyprogesterone Acetate. Journal of Pharmaceutical Sciences. 80(12). 1130–1132. 7 indexed citations
18.
Namer, Moïse. (1988). Clinical applications of antiandrogens. Journal of Steroid Biochemistry. 31(4). 719–729. 28 indexed citations
19.
Lagrange, Jean‐Léon, et al.. (1987). Pulmonary toxicity of a combination of low-dose doxorubicin and irradiation for inoperable lung cancer. Radiotherapy and Oncology. 9(4). 281–288. 25 indexed citations
20.
Courdi, A., C.M. Lalanne, Jean–Louis Fischel, et al.. (1985). Establishment, characterization, chemosensitivity, and radiosensitivity of two different cell lines derived from a human breast cancer biopsy.. PubMed. 45(3). 1246–58. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Rose Breakdown of academic impact, for papers by David L. Ahmann Breakdown of academic impact, for papers by D C Tormey Breakdown of academic impact, for papers by Reena S. Cecchini Breakdown of academic impact, for papers by Darcy Spicer Breakdown of academic impact, for papers by Elisabet Lidbrink Breakdown of academic impact, for papers by Tom Meade Breakdown of academic impact, for papers by Jeremy Braybrooke Breakdown of academic impact, for papers by Takuma Nemoto Breakdown of academic impact, for papers by Harriet Johansson
Rankless by CCL
2026